| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 6.62 | 1404.5% | 15.7% |
| Total Income | 6.62 | 1404.5% | 15.7% |
| Expenditure | 10.78 | 0.0% | 12.3% |
| PBT | -11.51 | 6.7% | 75.5% |
| Net Profit | -11.52 | 6.8% | 75.6% |
| OPM | -62.69% | ||
| NPM | — | ||
| EPS | -4.12 | 38.5% | 610.3% |
Lifeward Reports Strong Second Quarter 2026 Financial Results
14 Aug 2026 · 14 Aug, 7:01 pm
Summary
Lifeward Ltd. reported a 16% increase in revenue to $6.6 million for the second quarter of 2026 compared to the prior year. The company strengthened its balance sheet with a proforma cash balance of approximately $11 million. While gross margin decreased slightly to 41% from 44%, total operating expenses saw a significant decline of 24% to $6.9 million. The net loss widened to $11.5 million ($4.12 per share) from $6.6 million ($7.01 per share) in the prior year, primarily due to non-cash fair value charges. Management expressed optimism about continued revenue momentum in the second half of 2026.
Key Highlights
- 1
Revenue increased 16% to $6.6 million in the second quarter of 2026 compared to the second quarter of 2025, marking the strongest quarterly revenue performance since the fourth quarter of 2024.
- 2
The Company strengthened its balance sheet to a proforma cash balance of approximately $11 million as of June 30, 2026.
- 3
Lifeward launched a pilot program with Ottobock Care in August 2026, broadening access to ReWalk Personal Exoskeleton across the country.
- 4
The ORMD-0801 oral insulin clinical program is advancing with preparations ongoing for the planned Phase 2 U.S. clinical trial.
- 5
Gross margin was 41% during the second quarter of 2026, compared to 44% in the second quarter of 2025.
- 6
Total operating expenses in the second quarter of 2026 declined 24% to $6.9 million, compared to $9.1 million in the second quarter of 2025.
- 7
Net loss was $11.5 million, or $4.12 per share, in the second quarter of 2026, compared to $6.6 million, or $7.01 per share, in the second quarter of 2025.
Management Comments
Mark Grant
The second quarter marks another important milestone in Lifeward's transformation into a scaled restorative healthcare company, with revenue growth demonstrating that the strategy we have implemented is working. Backed by a strong sales pipeline, we expect this revenue momentum to continue in the second half of 2026. Over the past year, we have strengthened Lifeward’s restorative healthcare platform, which includes multiple commercial products, a strong reimbursement infrastructure, a scalable capital-efficient distribution model and an exciting pipeline of potential future rehabilitation technologies. These capabilities create a powerful foundation that we believe will support sustainable long-term growth and expand access to life-changing technologies for patients around the world. As part of the governance changes announced today, I am proud of what our team has accomplished together with the support and guidance of our board. We have established the strategy, strengthened the balance sheet, built the commercial infrastructure and positioned the Company to capitalize on significant opportunities ahead.
Informational and educational content only. Not investment advice.